split-banner-image

PALLAS

Closed

ANZ 1603/ABCSG 42: PALLAS

BCT Study Chair:

Nicholas Zdenkowski

An international clinical trial, open to both women and men diagnosed with Hormone Receptor (HR) positive, Human Epidermal Growth Factor Receptor 2 (HER2) negative, early stage breast cancer. PALLAS aims to find out if patients with early stage breast cancer could benefit from receiving 2 years of Palbociclib along with standard hormone treatment, compared with standard hormone treatment alone.

international

5361

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

434

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

21

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

PALLAS PUBLICATIONS

2024

Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).

Metzger O, Ballman KV, Gnant M, Watson M, Chen E, Tran K, O’Brien P, Hlauschek D, Martin M, Balko JM, sowecki Z, Hahn OM, Denkert C, Curtis C, Liu Y, Dueck AC, Fesl C, Mayer EL, DeMichele A, Symmans WF. Journal of Clinical Oncology 2024; 42(suppl 16).:ASCO 2024, 538; 10.1200/JCO.2024.42.16_suppl.538, Abstract

2023

Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer.

Stover D, Hlauschek D, Mayer E, Symmans W, Watson M, Barozzi I, Filipits M, Ballman K, Bellet-Ezquerra M, Balko J, Rubovsky G, Zdenkowski N, Furfsky A, Steger G, Isaacs C, Loibl S, Henao F, Regan M, Liu Y, Fesl C, O’Brien P, DeMichele A, Gnant M, Metzger O. SABCS 2023; GS03-07, Abstract

Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05).

Kantor O, Fayanju O, Dueck A, Gnant M, Burstein H, Goetz M, Isaacs C, Shepherd L, Hahn O, Anderson D, Miller K, Rugo H, Traina T, Dayao Z, Clifton K, Winer E, Wolff A, Wolmark N, Lu D, O’Brien P, Scovil S, DeMichele A, Mayer E. SABCS 2023; PO3-02-05, Abstract

Clinical characterization, prognostic and predictive values of HER2-low in early breast cancer in the PALLAS trial.

Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, Pfeiler G, Marin M, Balko J, Nowecki Z, Balic M, Brufsky A, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Solkner L, Fesl C, Mayer E, Gnant M. SABCS 2023; PO1-01-13, Abstract

The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study.

Agostinetto E, Pfeiler G, Hlauschek D, Mayer E, Lambertini M, de Azambuja E, Bellet-Ezquerra M, Meisel J, Rubovsky G, Zdenkowski N, Novik Y, Riz-Borrego M, Gelmon K, Mamounas E, Iwata H, Lu D, Solkner L, Fesl C, Gnant M, DeMichele A. SABCS. 2023; PO1-01-08, Abstract

Impact of BMI in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Stroble S, Martin M, Meisel JL, Zdenkowski N, Loible S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon KA, Goetz M, Haddad TC, Iwata H, Jassem J, Lee S-C, Linderholm B, Los M, Mamounas EP, Miller KD, Morris PG, et al.; on behalf of the PALLAS Groups and Investigators. Journal of Clinical Oncology. 2023; 41(33):5118-5130, DOI https://doi.org/10.1200/JCO.23.00126, Journal

LOAD MORE

Institutions